GE HealthCare’s $945 Million Sofie Acquisition Signals Growing Demand for Specialised Healthcare Facilities

GE HealthCare is making a major move into the expanding radiopharmaceutical market, agreeing to acquire Sofie Biosciences for $945 million in cash. The transaction, announced on October 5, is expected to close in the first half of 2027, subject to regulatory approvals.

Sofie operates a specialised U.S. manufacturing and distribution network for radiopharmaceuticals used in PET imaging. Its footprint includes 15 contract manufacturing sites and 21 cyclotrons, facilities that produce radioactive compounds used to help clinicians detect and assess diseases, including cancer.

For the property sector, the deal highlights a less visible but increasingly important part of healthcare real estate. Radiopharmaceutical facilities cannot operate like conventional warehouses or pharmaceutical offices. They require specialised production environments, radiation-safety infrastructure, controlled areas, sophisticated equipment and reliable distribution networks.

Location is also critical. Many PET radiopharmaceuticals have extremely short lifespans, making rapid movement from production facilities to hospitals and imaging centres essential. GE HealthCare says the acquisition will give it a stronger “final mile” footprint in the U.S. supply chain.

The acquisition also includes U.S. rights to FAPI-74, a Phase III PET imaging agent being developed with potential applications across multiple cancers.

As precision medicine expands, healthcare real estate may increasingly need to accommodate highly specialised facilities. GE HealthCare’s latest acquisition demonstrates how advances in medical treatment can create demand not only for new technologies, but also for the specialised properties and infrastructure required to deliver them.